Observational studyESC heart failure2026
An integrated Biobank in the Swedish Heart Failure Registry-clinomics, proteomics, transcriptomics and genomics.
Observational study in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06435585 (Responders and Non-responders in the Management of Heart Failure - Significance of Genetic Influence and Identification of Novel Informative Biomarkers), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Responders and Non-responders in the Management of Heart Failure - Significance of Genetic Influence and Identification of Novel Informative Biomarkers
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo build a comprehensive biobank integrated in the Swedish Heart Failure Registry (SwedeHF) comprising comprehensive clinomic data, proteomic, transcriptomic and genomic information in combination with clinical and diagnostic characteristics and additional ICD-code registry data.
methodsBlood and urine samples will be biobanked at SwedeHF registration with an optional second sampling after 6 months in patients with HF attending routine clinical visits at nine hospitals with access to healthcare integrated biobanking. Circulating and urine biomarkers will be investigated by proteomic, metabolomic, transcriptomic profiling, explored with genetic data. Sample size assessments were based on the BIOSTAT-CHF cohort and doubled to fulfil all aims targeting 5000 patients.
resultsThe first 1348 enrolled patients were median 72 years, 30% females, 65% HFrEF and 11% HFpEF. Median NT-proBNP was 1240 (quartile 1-3; 470-2830) pg/mL. This was comparable to the 8506 patients with an index registration in SwedeHF during 2023 with 52% HFrEF and 20% HFpEF, age 75 years, 36% females and NT-proBNP 1560 [629-3617] pg/mL.
conclusionsWe are building a high-quality detailed biobank linked to SwedeHF, the world's largest continuous HF registry, consisting of plasma, serum, whole blood and urine samples. The Biobank will enable studies exploring underlying disease mechanisms in HF and response to HF treatment, paving the way for precision medicine and novel drug targets. It will also generate a structure for biobanking in Registry-based Randomized Controlled Trials within the national SwedeHF registry. CLINICALTRIALS.GOV IDENTIFIER: NCT06435585.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.